Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2009

View Archived Issues

Ex vivo IL-10 gene therapy correlates with functional repair of lung transplants

CH-5137291evaluated in preclinical models of castration-resistant prostate cancer

E-3810 exhibits potent antiangiogenic activity in preclinical studies

Favorable safety and lipid profiles with anacetrapib therapy in hyperlipidemia

Pioglitazone slows atherosclerosis progression in type 2 diabetes patients

Vasopressin V1a and V1b receptor antagonists reported by sanofi-aventis

Schering-Plough claims A2A receptor antagonists for the treatment of PD

Novel histamine receptor modulators in early development at Medivation

5-HT, DA and NE reuptake inhibitors disclosed by GSK for the treatment of anxiety

Vertex is developing ABC transporter modulators for the treatment of cystic fibrosis

Advanced BioHealing initiates prospective clinical trial for venous leg ulcers

Alkermes initiates phase II trial of ALKS-33 for alcohol dependence

Anacor starts phase I trial of AN-3365 for Gram-negative infections

Albireo presents clinical data on A-3309 in chronic idiopathic constipation

Pluristem Therapeutics reports 3-month follow-up data for PLX-PAD

Vivus reports results from phase III avanafil study in erectile dysfunction

Genzyme reports results from phase II/III trial of GENZ-644470 in hyperphosphatemia

Asterand to acquire BioSeek

Biocompatibles acquires Astron Clinica's inventory and intellectual property assets

FDA issues complete response to Genentech and Biogen's applications for rituximab in CLL

FDA committee votes that data for Prevnar 13 vaccine support safety and effectiveness

Sangamo presents update on phase I safety study of SB-728-T for HIV/AIDS

Chugai files for additional indication for Epogin in Japan

deCODE genetics files for bankruptcy in the U.S.

ImmuPharma reports final results from phase IIb trial of Lupuzor in SLE

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...